tiprankstipranks
Advertisement
Advertisement

MDGL Stock Latest News

Madrigal Pharmaceuticals price target lowered to $543 from $553 at BofA
The FlyMadrigal Pharmaceuticals price target lowered to $543 from $553 at BofA
2d ago
MDGL
Madrigal Therapeutics: Rezdiffra’s Expanding MASH Opportunity Supports Reiterated Buy Rating and Unchanged $620 Price Target
PremiumRatings
Madrigal Therapeutics: Rezdiffra’s Expanding MASH Opportunity Supports Reiterated Buy Rating and Unchanged $620 Price Target
2d ago
MDGL
Neutral Stance Maintained as Madrigal’s Growth Prospects Tempered; Price Target Trimmed from $553 to $543
PremiumRatings
Neutral Stance Maintained as Madrigal’s Growth Prospects Tempered; Price Target Trimmed from $553 to $543
2d ago
MDGL
MDGL: Rezdiffra’s Strong Q2 Momentum, Robust Cash Position, and Expanding MASH Market Penetration Underpin TD Cowen Buy Rating
PremiumRatings
MDGL: Rezdiffra’s Strong Q2 Momentum, Robust Cash Position, and Expanding MASH Market Penetration Underpin TD Cowen Buy Rating
2d ago
MDGL
Madrigal Pharmaceuticals reports Q2 EPS ($1.99), consensus ($2.23)
PremiumThe Fly
Madrigal Pharmaceuticals reports Q2 EPS ($1.99), consensus ($2.23)
3d ago
MDGL
Madrigal Pharmaceuticals price target raised to $587 from $578 at Canaccord
PremiumThe FlyMadrigal Pharmaceuticals price target raised to $587 from $578 at Canaccord
4d ago
MDGL
MDGL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
MDGL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
5d ago
MDGL
Madrigal Pharmaceuticals initiated with an Overweight at Wells Fargo
Premium
The Fly
Madrigal Pharmaceuticals initiated with an Overweight at Wells Fargo
6d ago
MDGL
Madrigal Pharmaceuticals price target raised to $553 from $542 at BofA
PremiumThe Fly
Madrigal Pharmaceuticals price target raised to $553 from $542 at BofA
11d ago
MDGL
Madrigal Pharmaceuticals price target raised to $739 from $737 at Citizens
PremiumThe Fly
Madrigal Pharmaceuticals price target raised to $739 from $737 at Citizens
16d ago
MDGL
Madrigal Pharmaceuticals announces three new resmetirom patents
PremiumThe Fly
Madrigal Pharmaceuticals announces three new resmetirom patents
20d ago
MDGL
Madrigal Shareholders Approve 2026 Equity Compensation Plans
PremiumCompany Announcements
Madrigal Shareholders Approve 2026 Equity Compensation Plans
2M ago
8K
MDGL
Madrigal Pharmaceuticals management to meet with Piper Sandler
PremiumThe FlyMadrigal Pharmaceuticals management to meet with Piper Sandler
2M ago
MDGL
Madrigal Pharmaceuticals price target lowered to $542 from $550 at BofA
Premium
The Fly
Madrigal Pharmaceuticals price target lowered to $542 from $550 at BofA
2M ago
MDGL
Analyst Reiterates Buy on Madrigal Pharmaceuticals, Maintains $620 Price Target on Strengthened Rezdiffra MASH and Cardiometabolic Data
Premium
Ratings
Analyst Reiterates Buy on Madrigal Pharmaceuticals, Maintains $620 Price Target on Strengthened Rezdiffra MASH and Cardiometabolic Data
2M ago
MDGL
Madrigal Pharmaceuticals announces new analyses of Rezdiffra data
PremiumThe Fly
Madrigal Pharmaceuticals announces new analyses of Rezdiffra data
2M ago
MDGL
Madrigal’s Rezdiffra Drives Blockbuster Growth Amid Costs
PremiumCompany Announcements
Madrigal’s Rezdiffra Drives Blockbuster Growth Amid Costs
2M ago
MDGL
Paulson takes new stake in Amicus, cuts position in Madrigal Pharma
PremiumThe Fly
Paulson takes new stake in Amicus, cuts position in Madrigal Pharma
3M ago
BHC
Madrigal Pharmaceuticals price target raised to $709 from $640 at Truist
PremiumThe Fly
Madrigal Pharmaceuticals price target raised to $709 from $640 at Truist
3M ago
MDGL
Madrigal Pharmaceuticals price target lowered to $578 from $587 at Canaccord
PremiumThe FlyMadrigal Pharmaceuticals price target lowered to $578 from $587 at Canaccord
3M ago
MDGL
Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI
Premium
The Fly
Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI
3M ago
MDGL
Madrigal Pharmaceuticals reports Q1 EPS ($3.25), consensus ($4.14)
Premium
The Fly
Madrigal Pharmaceuticals reports Q1 EPS ($3.25), consensus ($4.14)
3M ago
MDGL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >